CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES

Today Chronic Myeloid Leukemia (CML) relapse's final assessment and monitoring in the whole world is implemented by BCR-ABL gene quantitative detection - during the polymerase chain reaction (by PSR means). Implementation of this monitoring materially and technically is not often available and remission during years is being assessed using monthly clinical-laboratory data. Proceeding from this, the goal of our work was to find the clinical-laboratory features, indicating the expected relapse and require the urgent molecular research carry out. In order to find the clinical-hematologic indicators of the Chronic Myeloid Leukemia expected relapse, BCR-ABL gene quantitative determination using the PSR method after the Imatinib treatment was done in 64 patients with CML who had remission (duration 0,5-14 years). The retrospective analyses of clinical-laboratory data was also held before the research. According to the molecular research results, we have set the risk groups of the patients - low, moderate and high risk groups. In the groups we have found the clinical-laboratory changes, existed before the research. We have held the comparative analyses of the molecular research in groups and the clinical-laboratory changes in them. As a result, we have established, that moderate anemia (expressed often during the whole remission period among the patients of all three risk groups) does not indicate the expected relapse and that in the Chronic Myeloid Leukemia remission period the expected relapse indicator could be the patient's Imatinib irregular intakes, non-systemic treatment and high, inexplicable progressive thrombocytosis in peripheral blood. These factors indicate the necessity to hold the urgent molecular research in order to define the post-treatment tactics.